A patient has an ultra-rare genetic disorder for w...
Guiding State PSC aspirants since 2016 50,000+ students · 1,000+ final selections Exam Calendar Results Call 9116926003
pscnotes
Pick your state
GPSC Prelims previous year questions

A patient has an ultra-rare genetic disorder for which conventional randomized clinical trials are difficult because of the extremely small patient population. Which of the following recent developments is particularly relevant regarding US FDA?

Asked in GPSC Senior Drugs Inspector, Class-2 2026

  1. FDA has completely eliminated evidence requirements for ultra-rare diseases.
  2. FDA has proposed a framework supporting development of individualized therapies when conventional randomized trials may not be feasible
  3. FDA has prohibited genome-editing therapies for ultra-rare diseases
  4. Individualized therapies are limited to conventional small-molecule drugs

Answer under review: our editors are checking this question. Try the other GPSC Prelims previous year questions questions meanwhile.

More GPSC Prelims previous year questions questions

All 27,588 GPSC Prelims previous year questions questions →